Zevra Therapeutics, Inc. (ZVRA) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on March 4, 2026, by Zevra Therapeutics, Inc., a Delaware corporation. The filing primarily addresses the appointment of a new Chief Financial Officer and references the upcoming announcement of financial results for the fourth quarter ended December 31, 2025.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within a press release dated March 9, 2026, which is furnished as Exhibit 99.1 but is not incorporated by reference into this filing.
Material Changes and Corporate Updates
- Executive Appointment: Justin Renz was appointed as Chief Financial Officer and Treasurer, effective March 9, 2026. He will serve as the principal financial officer effective March 10, 2026.
- Leadership Transition: Timothy Sangiovanni, currently the Senior Vice President, Finance and Corporate Controller, will cease serving as the principal financial officer effective March 10, 2026.
- Compensation Package: Mr. Renz's annualized base salary is $520,000 with a target annual performance bonus of 45%. He received an option to purchase 300,000 shares of common stock, vesting over four years.
- Severance Terms: In the event of termination without cause or resignation for good reason, Mr. Renz is eligible for 12 months of base salary, a prorated bonus, and accelerated vesting of stock awards.
Guidance, Outlook, and Risks
The filing does not contain specific guidance, outlook, or risk factors. It notes that a press release detailing financial results and corporate updates for the fourth quarter of 2025 was issued on March 9, 2026, and a conference call was scheduled for that date. No unusual items or contingencies are described in the text of this 8-K.
Investor Verification Checklist
- Review the March 9, 2026 press release (Exhibit 99.1) for actual Q4 2025 financial results, as they are not included in this filing.
- Verify the terms of the Employment Agreement (Exhibit 10.1) for full details on Mr. Renz's compensation and severance.
- Monitor the transition of the principal financial officer role from Timothy Sangiovanni to Justin Renz effective March 10, 2026.
- Check for any subsequent filings regarding the March 9, 2026 conference call transcript for management commentary on the company's outlook.